Taisho Pharmaceutical Holdings

Taisho Pharmaceutical Holdings is a prominent manufacturer of specialty and generic drugs, primarily focused on the production and sale of self-medication products. The company's portfolio includes a variety of well-known items, such as cold medicines, allergy medications, and dietary supplements like the Lipovitan and Pabron series. Operating through two main segments—Self-Medication and Prescription Pharmaceuticals—Taisho derives the majority of its revenue from the Self-Medication segment, catering primarily to external customers in Japan. The company also explores mergers and acquisitions as a strategy to enhance its research, development, manufacturing, and marketing capabilities.

Akira Uehara

Chairman, President and CEO

10 past transactions

Biolinq

Series C in 2025
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Biolinq

Venture Round in 2024
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

VIE STYLE

Series A in 2024
VIE STYLE offers wearable music device and AI technology services.

AuB

Series C in 2022
AuB, Inc. is a company based in Chuo, Japan, founded in 2015, that specializes in the research and development of supplements, food, and beverages aimed at enhancing the intestinal environment of athletes. The company focuses on analyzing intestinal microflora to support improved athletic performance and overall health. AuB develops health supplements and cosmetics derived from microbiome studies and stool sample analyses, and offers dietary improvement services tailored to the specific needs of athletes based on their intestinal flora data. Through these innovative products and services, AuB aims to promote better nutrition and health, ultimately contributing to enhanced athletic performance.

Biolinq

Series B in 2021
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Moodify

Series A in 2021
Moodify Ltd is a Tel Aviv-based company founded in 2017 that develops an artificial intelligence platform focused on creating scents to enhance consumer experiences. By leveraging 15 years of neuroscience research from the Weizmann Institute and advanced bioinformatics machine learning technologies, Moodify transforms scent production to be more efficient, sustainable, and effective. The company's active scents utilize non-invasive and safe signals that engage the olfactory sense, allowing brands and fragrance houses to design and control scent experiences for their products. This innovative approach aims to provide cognitive behavioral therapy through artificial empathy, improving the overall effectiveness of consumer products.

aiwell

Series A in 2020
aiwell Inc. specializes in AI proteomics, focusing on the research and development of technologies that reveal biological changes through protein analysis. The company has developed a platform that digitalizes proteins from both humans and livestock, facilitating sample processing, small-volume analysis, and comparative image data analysis. Among its offerings is aiwell care, a micro blood sampling kit that enables users to conduct blood tests conveniently. aiwell provides AI-driven support for diagnosis, drug discovery, and remote medical care, enhancing the capabilities of medical practitioners. The company also collaborates with the Tokyo Institute of Technology to advance its research initiatives. Founded in 2018 and based in Tokyo, Japan, aiwell was previously known as CF Partners Co., Ltd. before rebranding in August 2018.

Nanotis

Series A in 2020
Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices, particularly for infectious diseases such as influenza. The company manufactures microchip devices that allow users to achieve rapid and accurate diagnoses, which are essential for medical professionals in practical healthcare settings. By providing timely information, Nanotis aims to enhance the efficiency of healthcare delivery and assist individuals facing health challenges.

Quantum Operation

Corporate Round in 2020
Quantum Operation, Inc. is a Tokyo-based company founded in 2017 that specializes in the development of innovative IoT wearable devices, particularly for blood sugar level management. The company focuses on creating smart watches designed to enhance diabetes management by minimizing the need for painful needle sticks. In addition to its healthcare technology, Quantum Operation also develops speech recognition systems, digital signage solutions, and AI surveillance cameras. Furthermore, the company provides IoT consulting services and engages in YouTuber movie production, showcasing its diverse capabilities within the technology sector.

UPSA SAS

Acquisition in 2018
UPSA SAS is a company focused on addressing pain and self-medication through its range of products. It manufactures over-the-counter medicines aimed at various health issues, including flu, vitality, digestion, and sleep quality. The company offers pharmaceuticals, food supplements, and medical devices designed for patients of all ages, from infants to seniors. By providing these products, UPSA SAS aims to support both consumers and pharmacists in managing everyday health challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.